Menest Shortage Update: What Patients Need to Know in 2026

If you've been struggling to find Menest (esterified estrogens) at your pharmacy, you're not imagining things. While Menest is not formally listed on the FDA's drug shortage database as of early 2026, patients across the country are reporting difficulty filling prescriptions due to broader supply chain pressures affecting the entire hormone replacement therapy (HRT) market.

Here's everything you need to know as a patient — the current situation, the history behind it, and what you can do to protect your supply.

Current Status: Is Menest in Shortage in 2026?

As of early 2026, Menest (esterified estrogens) is not on the FDA's official drug shortage list. However, "not listed" does not mean "easy to find." Real-world availability has been inconsistent at many pharmacy locations — particularly large chain pharmacies — due to the following:

Surging demand for all HRT products, with estrogen prescriptions up 184% from 2018–2026 for women aged 45–54

A concentrated manufacturing base — only a small number of companies produce generic esterified estrogen tablets

Demand spillover from the widespread estradiol patch shortage (affecting Climara, Vivelle-Dot, and generics) — patients unable to get patches are switching to oral estrogens

Chain pharmacies not consistently stocking lower-volume brand-name products like Menest

Timeline: How Did We Get Here?

The supply challenges with Menest didn't appear overnight. Here is a brief history:

Pre-2018: Estratab (a previous esterified estrogens brand) was discontinued, leaving Menest as the primary brand

~2018: Pfizer discontinued the 2.5 mg strength of Menest, reducing available dosage options

2020–2023: Growing public awareness of menopause treatment drives sharp increase in HRT prescriptions; telehealth menopause clinics expand access

2023–2025: Widespread estradiol patch shortages affect major brands and all generics; oral estrogens see spillover demand

November 2025: FDA removes black box warnings for cardiovascular disease, breast cancer, and probable dementia from menopausal HRT products — a major shift that prompts a new wave of patients to seek hormone therapy

Early 2026: HRT prescriptions surge another 20% (July 2025–Feb 2026); Menest availability inconsistent at many pharmacies

The FDA's November 2025 Label Change: What It Means for You

For years, HRT products including Menest carried bold black box warnings about cardiovascular disease, breast cancer, and probable dementia. In November 2025, the FDA initiated removal of these warnings, following years of clinical evidence suggesting the original warnings overstated risks for most menopausal women, particularly those under 60 and within 10 years of menopause onset.

One boxed warning remains: the endometrial cancer warning for estrogen-alone therapy in women who have a uterus. Women with an intact uterus should take a progestin alongside Menest to reduce this risk.

Which Strengths Are Affected?

Menest is currently available in three strengths: 0.3 mg, 0.625 mg, and 1.25 mg. The 0.625 mg tablet is the most commonly prescribed and typically easiest to source. The 0.3 mg and 1.25 mg strengths may face more limited availability at some locations. The 2.5 mg strength was permanently discontinued.

What Should Patients Do Right Now?

Try the generic first. Generic esterified estrogen tablets are the same medication as Menest and often easier to find. Ask your pharmacist specifically for the generic.

Call independent pharmacies. They have more ordering flexibility than chains and can often source medications within 1–2 business days.

Use medfinder. medfinder calls pharmacies near you to find which ones can fill your prescription.

Talk to your prescriber. If availability remains a problem, ask about switching to estradiol (Estrace) or conjugated estrogens (Premarin). Both may be more reliably available.

Consider mail order. Mail-order pharmacies typically have more consistent supply and offer 90-day fills, reducing monthly stress.

What's the Outlook for Availability in 2026?

The estrogen supply chain is gradually recovering, but the concentration of manufacturing among few producers means availability will likely remain inconsistent for Menest and other esterified estrogen products through 2026. Seasonal demand patterns can also spike in early fall. Planning ahead, maintaining 90-day supplies when possible, and having an alternative plan ready are the best patient strategies. For practical tools to help you find it today, see our guide: How to Find Menest in Stock Near You.